Undervalued Drug Manufacturer Stocks on NAS January 2024

January 21, 2024

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
SBFM Sunshine Biopharma 0.23 0.79 242.47 111767 6 0.00 0.0
DRRX Durect 0.77 1.90 146.02 314693 21 0.00 0.0
GRFS Grifols 6.75 16.49 144.36 4654341 0 0.00 164.4
BFRI Biofrontera 1.81 3.86 113.01 107142 2 0.00 0.0
EVOK Evoke Pharma 0.79 1.58 101.78 73414 3 0.00 0.0
ASRT Assertio Holdings 0.82 1.62 98.52 1536398 67 0.00 0.0
INCR Intercure 1.36 2.51 84.49 38526 68 0.00 11.6
CGC Canopy Gwth 4.44 8.13 83.20 3315919 318 0.00 0.0
SHPH Shuttle Pharmaceuticals 0.45 0.80 78.98 265017 7 0.00 0.0
TLRY Tilray Brands 1.94 3.47 78.92 32596997 1418 0.00 0.0
All data provided as at market close January 18, 2024.

Company Details

Sunshine Biopharma

SBFM:NAS

Close Price

0.23

Our Valuation

0.79

% Difference

242.47

Market Cap ($M)

6

P/E Ratio

0.0

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements.

Access the stockcalc valuation


Durect

DRRX:NAS

Close Price

0.77

Our Valuation

1.90

% Difference

146.02

Market Cap ($M)

21

P/E Ratio

0.0

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Access the stockcalc valuation


Grifols

GRFS:NAS

Close Price

6.75

Our Valuation

16.49

% Difference

144.36

Market Cap ($M)

0

P/E Ratio

164.4

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.

Access the stockcalc valuation


Biofrontera

BFRI:NAS

Close Price

1.81

Our Valuation

3.86

% Difference

113.01

Market Cap ($M)

2

P/E Ratio

0.0

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Evoke Pharma

EVOK:NAS

Close Price

0.79

Our Valuation

1.58

% Difference

101.78

Market Cap ($M)

3

P/E Ratio

0.0

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Access the stockcalc valuation


Assertio Holdings

ASRT:NAS

Close Price

0.82

Our Valuation

1.62

% Difference

98.52

Market Cap ($M)

67

P/E Ratio

0.0

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines.

Access the stockcalc valuation


Intercure

INCR:NAS

Close Price

1.36

Our Valuation

2.51

% Difference

84.49

Market Cap ($M)

68

P/E Ratio

11.6

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations.

Access the stockcalc valuation


Canopy Gwth

CGC:NAS

Close Price

4.44

Our Valuation

8.13

% Difference

83.20

Market Cap ($M)

318

P/E Ratio

0.0

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include sports drink BioSteel, skincare products under This Works, Martha Stewart CBD, and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S.

Access the stockcalc valuation


Shuttle Pharmaceuticals

SHPH:NAS

Close Price

0.45

Our Valuation

0.80

% Difference

78.98

Market Cap ($M)

7

P/E Ratio

0.0

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Access the stockcalc valuation


Tilray Brands

TLRY:NAS

Close Price

1.94

Our Valuation

3.47

% Difference

78.92

Market Cap ($M)

1418

P/E Ratio

0.0

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Sunshine Biopharma and Durect are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-january-2024
Sunshine Biopharma $SBFM and Durect $DRRX are the most undervalued Drug Manufacturers stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-january-2024
Sunshine Biopharma and Durect are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-january-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.